What you will actually pay

A ChondroFiller injection in the UK is priced across three published tiers, determined by how many boxes of collagen scaffold the defect requires. One box — covering defects of up to approximately 3 cm² — costs £3,000. Two boxes cost £5,500, and three boxes (up to 6 cm²) cost £8,000. Most patients presenting with a single focal knee defect require only one box, so £3,000 is where the majority of cases sit.

These figures are fixed and published openly — a level of pricing transparency that remains uncommon in UK private musculoskeletal care. The published price is the total cost: consultation, pre-procedure MRI review, real-time ultrasound guidance, the ChondroFiller implant itself, intravenous antibiotic cover, and a six-week follow-up are all included. There are no additional charges on the day of treatment.

For hip and shoulder joints, pricing is less uniformly set in advance. An indicative range of approximately £6,500–£9,500 or above is cited, though the figure for non-knee joints is confirmed only after MRI has established the defect dimensions and a personalised quote has been provided by the clinic.

What the price actually covers

Private orthopaedic procedures in the UK are commonly priced in parts. A surgical cartilage repair quote, for instance, typically covers the surgeon's fee but may exclude the anaesthetist, the post-operative physiotherapy course, and any follow-up imaging — costs that accumulate after the headline figure has already been agreed. The same fragmentation appears with many injectable treatments, where a consultation fee, an imaging fee, and a procedure fee are itemised and billed separately.

The ChondroFiller injection pathway works differently. Because the published price is structured as a single all-inclusive fee — covering each stage from initial specialist review through to the six-week follow-up — it is possible to compare it directly against alternatives without needing to reconstruct what a comparable episode of care would actually cost elsewhere. That reconstruction is often difficult: many UK private clinics do not publish cartilage repair costs at all, and those that do rarely present them in a way that accounts for all the associated charges.

For patients researching options across a range of prices, the practical implication is that the quoted figure for a ChondroFiller injection represents the full financial commitment — not a floor on which further charges will be added.

ChondroFiller injection vs private cartilage surgery

The surgical options most likely to be discussed alongside a ChondroFiller injection — microfracture, autologous chondrocyte implantation (ACI or MACI), and osteochondral autograft transfer (OATS) — are theatre-based procedures requiring general or regional anaesthesia, an operating team, and a formal rehabilitation programme. For the knee, private costs across UK providers typically range from £7,000 to £14,000. Many of those figures, as noted, do not account for the anaesthetist's fee, a course of post-operative physiotherapy, or follow-up imaging — meaning the comparable total cost of a surgical episode is commonly higher than the headline quoted. For non-knee joints, an approximate 30% uplift applies, putting indicative surgical costs from around £12,740 upwards.

The clinical data add a further dimension to the cost picture. Published outcome series for ChondroFiller injection report an IKDC improvement of approximately 30 points, a complication rate of approximately 0%, and a reoperation rate of 3–8%. Across the evidence base, 70–85% of treated patients achieve meaningful symptom relief at three to five years. The surgical comparators show wider variance: microfracture carries reoperation rates reported as high as 41%, while ACI and MACI are associated with complications in up to 17% of cases and reoperation rates up to 37%. These figures do not mean surgery is always the wrong choice — defect size, patient age, bone health, and individual anatomy all affect which pathway is appropriate — but they are relevant to a patient assessing the full cost and risk profile of each option.

The recovery difference carries its own financial weight. A ChondroFiller injection is delivered as an ultrasound-guided outpatient procedure, with a protect phase of approximately four to six weeks of limited weight-bearing. Surgical cartilage repair typically requires six to twelve months of structured rehabilitation before return to full activity. Lost earnings during that recovery window, and the cost of extended physiotherapy, are patient-borne and rarely appear in any published price comparison.

For patients trying to navigate these options, the absence of published pricing from many surgical providers makes direct like-for-like comparison genuinely difficult — a practical obstacle rather than a reflection on any particular technique.

ChondroFiller injection vs non-regenerative injections

Three injection types sit below ChondroFiller on the price scale: corticosteroid (typically £120–£200), PRP (£400–£800), and Arthrosamid, a polyacrylamide hydrogel licensed for knee osteoarthritis, at £2,100–£3,000. The price difference is explained by what each product does rather than by where it sits in a clinic's fee schedule.

Corticosteroid manages inflammation. PRP introduces growth factors that may support the tissue environment. Arthrosamid is a permanent non-regenerative hydrogel — it cushions the joint space but does not initiate cartilage repair. All three have legitimate clinical uses at the right patient stage; none carries a regenerative mechanism.

ChondroFiller is classified as a CE-marked Class III medical device — the highest tier under European medical-device regulation, reserved for products with an active biological function rather than simple structural or chemical effect. The scaffold gels within the defect and recruits the patient's own progenitor cells through acellular matrix-induced chondrogenesis. That biological role, and the regulatory and manufacturing requirements it demands of Meidrix Biomedicals GmbH, is what separates the £3,000 entry price from a £200 cortisone injection.

ChondroFiller and Arthrosamid are occasionally used in combination at a published guide cost of £6,000. When that pathway is appropriate, the two products are doing different jobs: ChondroFiller is the regenerative scaffold component; Arthrosamid addresses a separate mechanical role. They should not be treated as interchangeable or blended into a single category.

Patients whose damage or OA stage is better suited to a simpler injection may not need ChondroFiller. The cost premium is only relevant where the regenerative mechanism is clinically appropriate.

Advanced and combination pathways — what affects the final price

For patients with more complex pathology, the pricing picture extends beyond the three standard tiers. Two defined combination protocols are available at the London Cartilage Clinic, both reserved for presentations that a single agent cannot adequately address.

The CFI + Arthrosamid combination — a two-mechanism approach aimed at KL Grade III/IV osteoarthritis, with the two products doing different jobs in the joint as described in the previous section — is priced at £6,000. For the most challenging presentations, the Tri-Active Therapy adds mesenchymal stem cells to that combination, at a published guide cost of £11,000. Neither protocol is appropriate for the majority of patients with a straightforward focal defect; the clinical assessment, and specifically the MRI review, determines whether a combination approach is indicated at all.

The same MRI dependency governs the final box count for any presentation. Defect area cannot be reliably estimated without imaging, and that area is what assigns the price tier. A patient presenting with multi-compartment damage, non-knee anatomy, or concurrent OA should treat any pre-assessment figure as indicative until the post-MRI consultation confirms both the extent of the defect and the most appropriate pathway.

NHS, insurance, and how to take the next step

Self-funded is the baseline for ChondroFiller injection in the UK. There is no NHS commissioning decision currently in place, and the treatment is not covered as standard by Bupa or AXA.

Insurance approval is not impossible, but it requires the patient to take action before booking. Two CCSD billing codes are relevant: W3111 (cartilage regeneration with collagen scaffold) and W8500. As of October 2025, case-by-case approvals have been reported most frequently with Bupa, Aviva, and WPA — though outcomes vary, and those reports come from the treating clinic rather than from independent insurer data. Any patient with private medical cover should contact their insurer with both codes and request written pre-authorisation before proceeding; approval sought retrospectively is unlikely to be honoured.

Liquid Cartilage™ is delivered in the UK at the London Cartilage Clinic on Harley Street, where Professor Paul Y. F. Lee leads ChondroFiller injection. An initial assessment — including MRI review — is the necessary first step, since defect dimensions govern which price tier applies and determine whether ChondroFiller injection is the appropriate pathway at all. Patients can arrange that assessment via londoncartilage.com.

The appointment itself is most productive when patients arrive with any MRI scan completed within the preceding 18 months, a clear account of symptom history, and — for those with private cover — written confirmation of their insurer's position on the billing codes. The assessment is the point at which clinical judgement, not symptom severity alone, establishes whether the defect size, joint anatomy, and overall presentation make ChondroFiller injection the right option at this stage.